Science Journal of Clinical Medicine
Volume 6, Issue 6, November 2017, Pages: 116-119
Received: Sep. 1, 2017;
Accepted: Sep. 30, 2017;
Published: Nov. 13, 2017
Views 1580 Downloads 97
Deh Zhou Patricia, Laboratory of Histology-Embryology and Cytogenetics, UFR-Medical Sciences, University Félix Houphouët-Boigny, Abidjan, Côte d’Ivoire
Koffi Dago Pierre, Department of Endocrinology- Diabetology, University Teaching Hospital-Yopougon, Abidjan, Côte d’Ivoire
Kouassi Joël-Brice, Laboratory of Biochemistry, UFR-Medical Sciences, University Félix Houphouët-Boigny, Abidjan, Côte d’Ivoire
Montéomo Gnaté François, Laboratory of Animal Physiology, Pharmacology - Pharmacopoeia, UFR-Nature Sciences, University Nangui-Abrogoua, Abidjan, Côte d’Ivoire
Kouassi Franck, Department of Endocrinology- Diabetology, University Teaching Hospital-Yopougon, Abidjan, Côte d’Ivoire
Yao Assita, Department of Endocrinology- Diabetology, University Teaching Hospital-Yopougon, Abidjan, Côte d’Ivoire
Hué Adélaïde, Department of Endocrinology- Diabetology, University Teaching Hospital-Yopougon, Abidjan, Côte d’Ivoire
Abodo Jacko Rhedoor, Department of Endocrinology- Diabetology, University Teaching Hospital-Yopougon, Abidjan, Côte d’Ivoire
Yapi Ahoua, Laboratory of Animal Biology, UFR-Biosciences, University Félix Houphouët-Boigny, Abidjan, Côte d’Ivoire
Lokrou Adrien, Department of Endocrinology- Diabetology, University Teaching Hospital-Yopougon, Abidjan, Côte d’Ivoire
Diabetes is a real public health problem in the world. In Africa in general and in Côte d'Ivoire in particular, the management of diabetes is complicated by socio-economic difficulties. After the diagnosis of diabetes, its typing is carried out on the basis of clinical criteria. With the discovery of many subgroups of diabetes especially in Africa, the classification of diabetes is made difficult. This difficulty may raise questions about the adequacy of the therapeutic treatment of patients. The purpose of this study was to study mainly the contribution of basal C-peptidemia in the typing of diabetic subjects. The material concerned a population of 220 diabetics who carried out their peptide C assay and monitored at the Yopougon-ABIDJAN University and Hospital Center. Basal C-Peptidemia was assayed by competitive radio-immunoassay using the kit CIS –BIO Shering. The results revealed that the classification based on clinical signs was improved after the C-peptide assay. Indeed, after C-peptidemia, type 1 diabetics with low C-peptidemia (<0.5 ng/ml) and type 2 diabetics with normal C-peptidemia (0.5 ng/ml to 3 ng/ml). In conclusion, the determination of peptide C appears as an undeniable tool for better classification of diabetic patients. The results of C-peptidemia would direct the practitioner towards a more adequate treatment in the patients studied.
Deh Zhou Patricia,
Koffi Dago Pierre,
Montéomo Gnaté François,
Abodo Jacko Rhedoor,
Basic C-peptidemia and Diabetic Patients Classification, Science Journal of Clinical Medicine.
Vol. 6, No. 6,
2017, pp. 116-119.
Assamoi G. La C-peptidémie du diabète Noir africain: étude transversale chez 207 patients. Thèse Méd. Abidjan, 1991, 12-33p.
Awah PK. Diabète et médecine traditionnelle en Afrique. Soins de santé, Diabetes Voice, 2006; 51, 3: 24-26.
Berger B, Stenstrom G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000; 60: 687–693.
Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011; 34: 607–609.
Davis AK, Du Bose SN, Haller MJ, Miller KM, Di Meglio LA and al. Prevalence of detectable c-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015; 38:476-481.
Ducorps M., Ndong W., Jupkwo B., Belmejdoub G., Thiolet C., Mayaudon H., Bauduceau B. Etude du diabète au Cameroun. Les difficultés de classification en Afrique Med. Trop. 1996; 56: 264-270.
Greenbaum CJ, Beam CA, Boulware D and al. Type 1 Diabetes Trial Net Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes Trial Net data. Diabetes 2012; 61:2066–2073.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG. Random non-fasting C–peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med. 2016; 33:1554-8.
Jones AG, A. T. Hattersley. The clinical utility of C-peptide measurement in the care of patients with diabetes Diabet. Med. 2013; 30, 803-817.
Kuhtreiber WM, Washer SLL, Hsu E, et al. Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med. 2015; 32:1346–53.
Kulkarni CM, Patil S. Urinary C-peptide and urine C-peptide/creatinine ratio (UCPCR) are possible predictors of endogenous insulin secretion in T2DM subjects—a randomized study. Int J Pharma Bio Sci. 2016; 7:443-446.
Kumar S, Subhakumari KN. Role of anti-GAD, anti-IA2 antibodies and C-peptide in differentiating latent autoimmune diabetes in adults from type 2 diabetes mellitus. Int J Diabetes Dev Ctries. 2016; 36:313–9.
Lachin JM, McGee P, Palmer JP, DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes. 2014; 63:739–48.
Lee A, Morley J. Classification of type 2 diabetes by clinical response to metformin–troglitazone combination and C-peptide criteria. Endocr Pract 1999; 5: 305–313.
Leighton E, Sainsbury CAR, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Therapy, 2017, 8,(3): 475–487.
Little RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL et al. Standardization of C-peptide measurements. Clin Chem 2008; 54: 1023–1026.
Lokrou A. Guide de prise en charge des diabétiques. Collection santé, Editions Universitaires de Côte d’Ivoire, 2008; 212p.
10. Lokrou A, Toutou T, Ouédraogo Y. Complications du diabète sucré en milieu hospitalier en Côte d’Ivoire. Rev Fr Endocrinol Clin, 1988; 29,3: 205-10.
Ludvigsson J, Carlsson A, Forsander G, Ivarsson S, Kockum I and al. C-peptide in the classification of diabetes inchildren and adolescents. Pediatr Diabetes 2012; 13: 45–50.
Ludvigsson J, Carlsson A, Deli A and al. Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diabetes Res Clin Pract 2013; 100:203-209.
Palmer JP. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009; 25:325–328.
Papoz L., Lokrou A., Delcourt C., Poton-Sanchez A.,Darrack R., Toure IA, Cuisinier raynal JC. Clinical classification of diabetes in tropical west Africa. Res. Clin. Pract. France. 1998, 3, 39: 219-27.
Sabot O, Tourniaire J, Charrie A, Rebattu B, Jouve M, Ayzac L et al. C-peptide assays of the urine and plasma at baseline and under stimulation with glucagon in healthy subjects and diabetics). Presse Med 1990; 19: 860–863.
Tsimaratos M. Physiological effect of c-peptide. Nephrolog. 2004, 25, 5: 155-161.
Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012; 35: 465-470.
Wiedmeyer HM, Polonsky KS, Myers GL, Little RR, Greenbaum CJ et al. International comparison of C-peptide measurements. Clin Chem. 2007; 53: 784–787.